We believe that clinical adoption of psychedelic therapies represents an opportunity to reduce human suffering on an unprecedented scale.
The Psychedelic Action Task Force is a first-of-its-kind coalition of leading scientists and clinicians working to redress the UK mental health crisis by removing barriers to research and facilitating responsible access to novel psychiatric treatments, in line with the best available science.
Prof. David Nutt and Alex Adams
Co-founders, Psychedelic Action Task Force
Psychedelic Action is advocating for evidence-based drug policy reform.
It is also supporting efforts to revaluate current clinical paradigms and develop a roadmap to facilitate the integration of psychedelic therapies into the UK’s healthcare system.
*****
If you would like to be part of the largest scientist- and clinician-led movement of its kind, join us by clicking the link below and completing the short form.
CLINICAL WORKING GROUP
Comprising 250 world-leading scientists and clinicians across medical disciplines, including 100+ psychiatrists, our CWG is dedicated to addressing the most urgent issues facing healthcare and mental health innovation.
REGISTER OF PROFESSORS
Prof David Baldwin MA DM FRCPsych FHEA FRSA
University of Southampton
Prof Stephen Bazire FRPharmS FCMHP MBE
University of East Anglia
Prof Tristan BekinschteinMSc PhD
University of Cambridge
Prof Anthony Cleare BSc MBBS PhD FRCPsych
King's College London
Prof Philip Cowen MA PhD FRCPsych
University of Oxford
Prof Ilana CromeMA MPhil MD FRCPsych
Keele University
Prof Val Curran BSc MSc PhD
University College London
Prof Ravi Das BSc MSc PhD
University College London
Prof Bill Deakin PhD FRCPsych FMedSci
University of Manchester
Prof Barry Everitt ScD FRS FMedSci
University of Cambridge
Prof Karl J. Friston MBBS MA MRCPsych MAE FMedSci FRBS FRS
University College London
Prof Jeremy Hall MB BS PhD MRCPsych
Cardiff University
Prof Catherine Harmer DPhil MA DipLATHE
University of Oxford
Prof Paul Harrison DM FRCPsych FMedSci
University of Oxford
Prof Joseph Hayes MBChB MRCPsych PhD
University College London
Prof Oliver Howes BM BCh MRCPsych PhD DM FMedSci
King's College London
Prof Sunjeev Kamboj PhD
University College London
Prof Ross King BSc MSc PhD
University of Cambridge
Prof George Kirov MD PhD
Cardiff University
Prof Hilary Little BSc MSc PhD
King's College London
Prof David Luke BSc PhD FHEA CPsychol AFBPsS
University of Greenwich
Prof Charles A Marsden BSc MSc PhD DSc HonFBPhS
University of Nottingham
Prof John Marsden PhD PgDip(CBT)
King's College London
Prof Mitul Mehta MA PhD
King's College London
Prof Celia Morgan PhD
University of Exeter
Prof Jo Neill PhD
University of Manchester
Prof Dasha Nicholls MD(Res) FRCPsych FAED
Imperial College London
Prof David Nutt DM FRCP FRCPsych FMedSci DLaws
Imperial College London
Prof Muireann Quigley BSc MB ChB MA PhD
University of Birmingham
Prof Trevor Robbins CBE FRS FMedSci
University of Cambridge
Prof Emma Robinson BSc PhD
University of Bristol
Prof James Rucker BSc MBBS MRCPsych PhD
King's College London
Prof Deepak Srivastava PhD ScD FRSB
King's College London
Prof Clare Stanford PhD
University College London
Prof James Stone MBBS PhD FRCPsych
University of Sussex
Prof Adam R. Winstock MBBS BSc MSc MD MRCP MRCPsych FAChAM
University College London
Prof Allan Young MB ChB MPhil MD FRCPsych FRCPC
Imperial College London
Our StoryPsychedelic Action has been formed in the belief that current legislation, which prohibits the clinical use of psychedelic compounds (including MDMA, LSD, psilocybin and DMT) outside the context of research trials specifically licensed by the Home Office, is unjustifiable.
After more than 50 years of prohibition, criminalisation and stigmatisation, science is finally showing that certain psychedelics when used according to established protocols in clinical settings are not usually dangerous or harmful.
Instead, when used according to tested, safe and ethical guidelines, they are the next revolution in mental health treatment.
In the context of a growing mental health crisis and lack of adequate tools to treat a plethora of psychiatric conditions, including PTSD, depression, anxiety, and addiction, the potential of psychedelic therapies to treat such conditions - for which there is strong data in support - can no longer be ignored.
The UK is failing patients most at need, enduring the severe economic consequences of the mental health crisis, and missing an opportunity to be a pioneering hub for mental health treatment.
We believe the need for systemic change is now a moral imperative and that this should be led by clinicians and scientists, free from commercial and political influence.